跳至主要内容
临床试验/EUCTR2013-001685-42-DK
EUCTR2013-001685-42-DK进行中(未招募)不适用

Changes in coagulation and platelet reactivity in HIV-1 infected patients switching between abacavir and tenofovir containing antiretroviral regimens - TAPAS

Rigshospitalet0 个研究点开始时间: 2013年6月21日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • HIV-1 infected
  • Can understand and sign written informed consent
  • Between 35 and 70 years old at inclusion
  • Received one of the above mentioned antiretroviral regimens continuously = 6 months
  • HIV RNA < 400 copies/mL for = 6 months
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • Receiving anticoagulant therapy, ADP-receptor inhibitors, aspirin or NSAIDs
  • Previous ischemic heart disease, peripheral atherosclerotic disease or stroke
  • Coagulation disorder (e.g. hemophilia, factor V Leiden mutation)
  • Platelet count < 150 x 109/L during the past 6 months from inclusion
  • eGFR<70 during the past 6 months from inclusion
  • HLA-B*57:01 positive genotype
  • Hepatitis B or C positive during the past year from inclusion

研究者

相似试验